Wall Street Zen Downgrades MetaVia (NASDAQ:MTVA) to Sell

MetaVia (NASDAQ:MTVA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

MTVA has been the subject of several other reports. HC Wainwright upped their target price on MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $36.50.

MetaVia Trading Up 3.0%

Shares of MetaVia stock opened at $2.43 on Friday. MetaVia has a twelve month low of $2.32 and a twelve month high of $23.10. The company has a fifty day moving average price of $7.12 and a 200 day moving average price of $8.35. The stock has a market cap of $5.35 million, a price-to-earnings ratio of -0.29 and a beta of 0.27.

MetaVia (NASDAQ:MTVA) last announced its earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($2.86) by $1.32. Analysts forecast that MetaVia will post -3.9 earnings per share for the current year.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new position in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent SEC filing. Institutional investors and hedge funds own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.